FEB 22, 2018 6:00 AM PST

Testing for Soluble ST2: Opening New Perspectives for Cardiovascular Diseases

Presented at: Drug Discovery 2018
Speaker

Abstract

Heart failure (HF) is a major problem for our contemporary societies in terms of prevalence, mortality and cost. Natriuretic peptides are recognized biomarkers for the diagnosis of HF but also for risk stratification. Innovative biomarkers are studied to improve the sub-phenotyping of HF, to facilitate the diagnosis of HF with preserved ejection fraction, and to tailor therapeutic approaches. The soluble receptor of interleukin 33 (sST2) is one of these new biomarkers. In groups of patients at higher risk of HF (hypertension, diabetes), measurement of sST2 could identify patients requiring more sustained management. In the case of HF with reduced ejection fraction, sST2 would be a powerful marker for risk estimation but also to confirm treatment choice. In the case of HF with preserved ejection fraction, measurement of sST2 may be useful for confirming a diagnosis but also for the risk stratification of the patients and as companion marker for the treatment. Interestingly, the determination of the concentrations of sST2 is facilitated by the evolution of assays with new point of care testing methods. As for many innovative biomarkers, the transition of sS2T to routine testing requires strong multidiscilplinary exchanges with physicians.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
FEB 22, 2018 6:00 AM PST

Testing for Soluble ST2: Opening New Perspectives for Cardiovascular Diseases

Presented at: Drug Discovery 2018


Show Resources
Loading Comments...
Show Resources
Attendees